title: Lansoprazole and carbonic anhydrase IX inhibitors sinergize against human melanoma cells.
abstract: BACKGROUND
  Proton Pump Inhibitors (PPIs) reduce tumor acidity and therefore resistance of tumors to drugs. Carbonic Anhydrase IX (CA IX) inhibitors have proven to be effective against tumors, while tumor acidity might impair their full effectiveness.
  
  
  OBJECTIVE
  To analyze the effect of PPI/CA IX inhibitors combined treatment against human melanoma cells.
  
  
  METHODS
  The combination of Lansoprazole (LAN) and CA IX inhibitors (FC9-399A and S4) has been investigated in terms of cell proliferation inhibition and cell death in human melanoma cells.
  
  
  RESULTS
  The combination of these inhibitors was more effective than the single treatments in both inhibiting cell proliferation and in inducing cell death in human melanoma cells.
  
  
  CONCLUSIONS
  These results represent the first successful attempt in combining two different proton exchanger inhibitors.
  
  
  CONCLUSIONS
  This is the first evidence on the effectiveness of a new approach against tumors based on the combination of PPI and CA IX inhibitors, thus providing an alternative strategy against tumors.
authors.affiliation: a Department of Therapeutic Research and Medicine Evaluation , National Institute of Health , Rome , Italy and.
authors.forename: Cristina
authors.initials: C
authors.lastname: Federici
authors.affiliation: a Department of Therapeutic Research and Medicine Evaluation , National Institute of Health , Rome , Italy and.
authors.forename: Luana
authors.initials: L
authors.lastname: Lugini
authors.affiliation: a Department of Therapeutic Research and Medicine Evaluation , National Institute of Health , Rome , Italy and.
authors.forename: Maria Lucia
authors.initials: ML
authors.lastname: Marino
authors.affiliation: b NEUROFARBA Department, Sezione di Scienze Farmaceutiche, Università degli Studi di Firenze , Sesto Fiorentino (Florence) , Italy.
authors.forename: Fabrizio
authors.initials: F
authors.lastname: Carta
authors.affiliation: a Department of Therapeutic Research and Medicine Evaluation , National Institute of Health , Rome , Italy and.
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Iessi
authors.affiliation: a Department of Therapeutic Research and Medicine Evaluation , National Institute of Health , Rome , Italy and.
authors.forename: Tommaso
authors.initials: T
authors.lastname: Azzarito
authors.affiliation: b NEUROFARBA Department, Sezione di Scienze Farmaceutiche, Università degli Studi di Firenze , Sesto Fiorentino (Florence) , Italy.
authors.forename: Claudiu T
authors.initials: CT
authors.lastname: Supuran
authors.affiliation: a Department of Therapeutic Research and Medicine Evaluation , National Institute of Health , Rome , Italy and.
authors.forename: Stefano
authors.initials: S
authors.lastname: Fais
mesh_terms: D000951:Antigens, Neoplasm / Q000378:metabolism; D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D000071231:Carbonic Anhydrase IX / Q000037:antagonists & inhibitors* / Q000378:metabolism; D002257:Carbonic Anhydrase Inhibitors / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D016923:Cell Death / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004354:Drug Screening Assays, Antitumor; D004357:Drug Synergism; D006801:Humans; D064747:Lansoprazole / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology*; D015394:Molecular Structure; D013329:Structure-Activity Relationship
chemical_list: D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D002257:Carbonic Anhydrase Inhibitors; D064747:Lansoprazole; C089226:CA9 protein, human; D000071231:Carbonic Anhydrase IX
keywords: Anti-acid drugs; carbonic anhydrase IX inhibitors; lansoprazole; tumor acidity